Gamco Investors INC. ET AL lowered its stake in Pfizer Inc. (NYSE:PFE) by 3.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 309,531 shares of the biopharmaceutical company’s stock after selling 11,280 shares during the quarter. Gamco Investors INC. ET AL’s holdings in Pfizer were worth $13,511,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Advocacy Wealth Management Services LLC raised its holdings in shares of Pfizer by 48.2% in the 4th quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 258 shares in the last quarter. Contravisory Investment Management Inc. raised its holdings in shares of Pfizer by 182.6% during the 4th quarter. Contravisory Investment Management Inc. now owns 1,153 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 745 shares in the last quarter. Vestor Capital LLC purchased a new position in shares of Pfizer during the 3rd quarter valued at about $53,000. Arlington Partners LLC raised its holdings in shares of Pfizer by 64.7% during the 4th quarter. Arlington Partners LLC now owns 2,141 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 841 shares in the last quarter. Finally, Ironwood Financial llc raised its holdings in shares of Pfizer by 91.0% during the 4th quarter. Ironwood Financial llc now owns 2,229 shares of the biopharmaceutical company’s stock valued at $97,000 after buying an additional 1,062 shares in the last quarter. Institutional investors and hedge funds own 69.36% of the company’s stock.
In other Pfizer news, EVP Dawn Rogers sold 15,002 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $42.98, for a total transaction of $644,785.96. Following the completion of the sale, the executive vice president now owns 28,722 shares of the company’s stock, valued at $1,234,471.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mikael Dolsten sold 149,553 shares of the business’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $43.55, for a total value of $6,513,033.15. Following the sale, the insider now directly owns 390,097 shares of the company’s stock, valued at approximately $16,988,724.35. The disclosure for this sale can be found here. In the last quarter, insiders have sold 288,726 shares of company stock valued at $12,534,617. 0.09% of the stock is owned by company insiders.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, April 30th. The biopharmaceutical company reported $0.85 EPS for the quarter, beating analysts’ consensus estimates of $0.75 by $0.10. The company had revenue of $13.12 billion during the quarter, compared to analysts’ expectations of $13.01 billion. Pfizer had a return on equity of 26.54% and a net margin of 21.31%. Pfizer’s revenue for the quarter was up 1.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.77 earnings per share. Research analysts forecast that Pfizer Inc. will post 2.89 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 10th will be given a dividend of $0.36 per share. This represents a $1.44 dividend on an annualized basis and a yield of 3.54%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.
A number of equities analysts recently weighed in on the company. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $55.00 price objective on the stock in a report on Thursday, January 31st. Zacks Investment Research cut Pfizer from a “hold” rating to a “sell” rating in a report on Friday, January 25th. Credit Suisse Group reissued a “buy” rating and set a $48.00 price objective on shares of Pfizer in a report on Monday, May 6th. Barclays reissued a “hold” rating and set a $41.00 price objective on shares of Pfizer in a report on Thursday, May 9th. Finally, Bank of America raised their price objective on Pfizer from $45.00 to $48.00 and gave the company a “buy” rating in a report on Monday, April 1st. Fourteen equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $45.83.
COPYRIGHT VIOLATION WARNING: “Gamco Investors INC. ET AL Has $13.51 Million Holdings in Pfizer Inc. (PFE)” was published by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://dakotafinancialnews.com/2019/05/15/gamco-investors-inc-et-al-has-13-51-million-holdings-in-pfizer-inc-pfe.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.